Gastroparesis
is chronic, delayed gastric emptying during which food residues stayswithin the
stomach longer than typical; symptoms incorporates nausea and vomiting. Gastroparesis
can happen as a result of motor dysfunction, nerve damage or paralysis of the
stomach muscles, and is related with other systemic diseases (diabetes
mellitus) and surgical complications (gastrectomy). Haloperidol
is afirst effective agent in combination using standard analgesic and also
antiemetic agents for the gastroparesis treatment.
It is
the first randomizedstudy, double- blind trial to estimate the effectiveness of
haloperidol as an adjunctive therapy for the symptoms of gastroparesis and found
that compared with gastroparesis patients randomized to placebo, those who
received Haloperidol had a statistically significant decrease of nausea and
pain, withoutany side effects, implying that the addition
of haloperidol to conventional therapy was better than conventional therapy
alone.
The
study proposes that future research, with larger sample sizes, is needed to
evaluate the external validity of the findings.
Haloperidol as an adjunctive
therapy is best to placebo for symptoms of gastroparesis.
Story Source:
By William Rose/August 01, 2018
No comments:
Post a Comment